HDAC9 polypeptides and polynucleotides and uses thereof
AssigneeSloan-Kettering Institute for Cancer Research
InventorsVictoria M. Richon, Xianbo Zhou, Richard A. Rifkind, Paul A. Marks
Life of this patent
Estimating the term…
Abstract
The present invention features substantially pure HDAC9, HDAC9a, HDAC9(ΔNLS), HDAC9a(ΔNLS), an HDRP(ΔNLS) polypeptides, and isolated nucleic acid molecules encoding those polypeptides. The present invention also features vectors containing HDAC9, HDAC9a, HDAC9(ΔNLS), HDAC9a(ΔNLS), and HDRP(ΔNLS) nucleic acid sequences, and cells containing those vectors.
Claims18
An isolated or recombinant histone deacetylase polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:
- 2.
An isolated or recombinant histone deacetylase polypeptide comprising the amino acid sequence as set forth in SEQ ID NO:2.
An isolated or recombinant histone deacetylase polypeptide SEQ ID NO:
- 2, which comprises a histone deacetylase catalytic domain wherein said domain consist of amino acids 635 to 953 of SEQ ID NO:2.
An isolated or recombinant histone deacetylase polypeptide, wherein said polypeptide is encoded by a nucleotide sequence as set forth in SEQ ID NO:
- 1.
An isolated or recombinant histone deacetylase polypeptide, wherein said polypeptide comprises the amino acid sequence set forth in SEQ ID NO:2 lacking a nuclear localization signal.
An isolated or recombinant histone deacetylase polypeptide, wherein said polypeptide has at least 95% amino acid sequence identity to SEQ ID NO:2, and wherein said polypeptide exhibits at least one activity selected from the group consisting of histone deacetylase activity, transcription repressor activity, and ability to deacetylase cellular substrates.
Dependencies are inferred from the claim text.